Spanish Registry of Digestive Tumours RETUD

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Status: Enrolling

Conditions: Colorectal Cancer (CRC); Bile Duct Cancer; Hepatocellular Cancer (HCC); Digestive Cancers; Rectal Cancer; Pancreatic Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06711211

TTD-20-01 RETUD RETUD

Details and patient eligibility

About

The aim of this observational study is to assess the current state of digestive tumours in Spain. By doing so, it seeks to enhance the quality of care, optimize the diagnosis and treatment of digestive tumours, and identify opportunities for improvement that can benefit patients.

The study will investigate the epidemiological, biological, and clinical characteristics of digestive tumors diagnosed in patients aged 18 and older across healthcare centres in Spain. It also aims to generate knowledge and scientific evidence for events and situations that may impact on patients with digestive tumours (e.g. COVID-19 coronavirus pandemic).

Furthermore, subject to the patient's consent, biological samples may be collected for use in translational research projects and for the identification of molecular markers that may be useful in healthcare decision-making.

Full description

Data will be collected ambispectively, recording those patients who were diagnosed with digestive tumours before the start of the study (from 2017) and also those who are diagnosed after the start of the study.

Enrollment: 20,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients ≥18 years old diagnosed with oesophageal cancer, gastric cancer, pancreatic cancer, hepatocarcinoma, gallbladder and bile duct cancer, cancer of the small intestine, appendix and gastrointestinal stroma, colorectal cancer, anal canal cancer or digestive hereditary cancer.
• Written informed consent available.

Exclusion criteria

• Patient for whom, for whatever reason, it is not possible to know or obtain the information necessary to complete the data collection base.

Trial design

20,000 participants in 5 patient groups

Biliary Tract Cancer (BTC)

Description:

Patients diagnosed with cholangiocarcinoma or gallbladder carcinoma from 01-01-2017.

Hepatocellular Carcinoma (HCC)

Description:

Patients with hepatocellular carcinoma primary diagnosed from 01-01-2017 and treated with systemic therapy.

MSI-High Colorectal Cancer (MSI-H CRC)

Description:

Patients with MSI-High colorectal cancer (by PCR or IHQ) and primary pathological diagnosis from 01-01-2017.

Pancreatic Cancer

Description:

Patients with exocrine pancreatic cancer diagnosed from 01-01-2019.

Rectal Cancer

Description:

Patients diagnosed with rectal cancer from 01-01-2019.